Charles E. de Bock

The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia

Zahra Sheybani, Charles E. de Bock

au (code pays fourni par la source)

OutFOXing a FENDRR bender in T-ALL

Hansen J. Kosasih, Charles E. de Bock

ch, au (code pays fourni par la source)

Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts

Christopher M. Smith, Ben Watts, Kathryn Evans, Hansen J. Kosasih et autres

Abstract Although survival rates for acute lymphoblastic leukemia (ALL) have improved dramatically over the past 60 years, outcomes vary across different molecular subtypes and risk categories, and a significant number of patients remain difficult to treat. ROR1 is a receptor tyrosine kinase …

au, us (code pays fourni par la source)

IRF2BP2::JAK2 Defines a Novel Kinase‐Activating Fusion in Pediatric T‐Cell Acute Lymphoblastic Leukemia

Fatimah Jalud, Tasnia Ibnat, Kaitlyn Kew, Lauren Brown et autres

T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous and clinically aggressive malignancy, where outcomes remain poor for patients with early relapse or refractory disease. Although tyrosine kinase alterations represent potentially actionable lesions, understanding of their functional and therapeutic relevance in T-ALL …

au (code pays fourni par la source)

A new KAT on the block rewrites the epigenetic script in menin inhibitor‐resistant leukemia

Yizhou Huang, Charles E. de Bock

au (code pays fourni par la source)

Building a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators

Charles E. de Bock, Katherine S. Bridge, Nick van Gastel, Hélène F.E. Gleitz et autres

au, us, be, nl, gb, de (code pays fourni par la source)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia

Hansen J. Kosasih, Charles E. de Bock

au (code pays fourni par la source)

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal

Danielle R. Bond, Sean M. Burnard, Kumar Uddipto, Kooper V Hunt et autres

DNA hypomethylating agents (HMAs), such as azacytidine (AZA, 5-azacytidine) and decitabine (DAC, 2’-deoxy-5-azacytidine), are used to treat acute myeloid leukaemia (AML) and myelodysplastic neoplasm. However, low response rates and therapy-resistant relapse remain significant challenges [ 1 ]. Reasoning that HMA-resistant relapse could …

au (code pays fourni par la source)

Editorial Expression of Concern: Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress

Ling Dong, C C Jiang, Rick F. Thorne, Amanda Croft et autres

The Editors-in-Chief would like to alert the readers that concerns have been raised regarding some of the data presented in this article. Speficically: Fig. 2c Mel-CV and MM200 images appear highly similar; Fig. 5a IRE1α MM200 (lanes 4-6) and 6e Ets-1 Mel-KD …

au (code pays fourni par la source)

Patient‐derived xenografts: Practical considerations for preclinical drug testing

Charles E. de Bock

au (code pays fourni par la source)

FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome

Panpan Zhao, Yuanyuan Zhang, Yang Yu, Qing Zhang et autres

FAT1 cadherin exhibits dual tumor suppressor and oncogenic roles across various cancers, but its function in breast cancer remains unclear due to conflicting reports of mutational loss and overexpression. In this study, we demonstrate that FAT1 mRNA and protein levels are reduced …

cn, au (code pays fourni par la source)

TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia

Lukas Lauwereins, Quentin Van Thillo, Sofie Demeyer, Nicole Mentens et autres

be, au, fr, us (code pays fourni par la source)